Insider Selling: Seres Therapeutics, Inc. (NASDAQ:MCRB) CEO Sells 12,726 Shares of Stock

Seres Therapeutics, Inc. (NASDAQ:MCRB) CEO Eric D. Shaff sold 12,726 shares of Seres Therapeutics stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $0.81, for a total transaction of $10,308.06. Following the completion of the sale, the chief executive officer now owns 192,039 shares in the company, valued at $155,551.59. The trade was a 6.21 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Seres Therapeutics Stock Down 1.0 %

NASDAQ:MCRB opened at $0.80 on Friday. Seres Therapeutics, Inc. has a 12-month low of $0.54 and a 12-month high of $1.53. The firm has a market capitalization of $137.19 million, a price-to-earnings ratio of -3.49 and a beta of 2.11. The stock’s 50 day moving average price is $0.84 and its two-hundred day moving average price is $0.85.

Institutional Investors Weigh In On Seres Therapeutics

A number of large investors have recently added to or reduced their stakes in MCRB. Avantax Advisory Services Inc. boosted its position in Seres Therapeutics by 170.9% during the fourth quarter. Avantax Advisory Services Inc. now owns 45,179 shares of the biotechnology company’s stock worth $38,000 after purchasing an additional 28,500 shares during the period. Jane Street Group LLC boosted its holdings in shares of Seres Therapeutics by 181.4% during the 4th quarter. Jane Street Group LLC now owns 58,736 shares of the biotechnology company’s stock worth $49,000 after buying an additional 37,866 shares during the period. Virtu Financial LLC grew its stake in Seres Therapeutics by 44.8% in the 3rd quarter. Virtu Financial LLC now owns 58,791 shares of the biotechnology company’s stock valued at $56,000 after buying an additional 18,191 shares during the last quarter. Providence Wealth Advisors LLC raised its holdings in Seres Therapeutics by 29.2% in the 3rd quarter. Providence Wealth Advisors LLC now owns 98,500 shares of the biotechnology company’s stock valued at $93,000 after acquiring an additional 22,250 shares during the period. Finally, Northern Trust Corp lifted its position in Seres Therapeutics by 20.4% during the fourth quarter. Northern Trust Corp now owns 262,683 shares of the biotechnology company’s stock worth $218,000 after acquiring an additional 44,461 shares during the last quarter. Institutional investors own 59.34% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on the company. Canaccord Genuity Group reiterated a “buy” rating and set a $10.00 target price on shares of Seres Therapeutics in a report on Thursday, November 14th. Chardan Capital reissued a “buy” rating and issued a $1.25 price objective on shares of Seres Therapeutics in a report on Wednesday, November 13th. Finally, StockNews.com upgraded shares of Seres Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, February 14th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and two have issued a buy rating to the company’s stock. Based on data from MarketBeat, Seres Therapeutics presently has a consensus rating of “Hold” and an average target price of $5.08.

Seres Therapeutics Company Profile

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.